Published in Pharma Law Weekly, January 12th, 2004
The patent entails a complete product concept that includes the route of administration, delivery device, and formulation.
U.S. Patent No. 6,610,271 was issued to a major university with whom ITI contracted to research and develop the lorazepam nasal spray. The patent's inventor is Daniel Wermeling, PharmD, ITI's chief operating officer. ITI holds a worldwide exclusive license to market the lorazepam delivery system and intends to sublicense the product to marketing partners. ITI has filed a continuation-in-part to have other...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Pharma Law Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.